


RECEIVED
CENTRAL FAX CENTER
APR 28 2008

I. Amendments to the Claims

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (Currently Amended) A compound of Formula I, or a salt, ~~solvate or hydrate~~ thereof:



wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-6} alkyl, C_{1-6} alkoxy, NH_2 , $NH-C_{1-6}$ alkyl, $N(C_{1-6}alkyl)(C_{1-6}alkyl)$, SH, $S-C_{1-6}alkyl$, NO_2 , CF_3 , OCF_3 and halo;

R^4 is unsubstituted Ar, or Ar substituted with 1-4 substituents, independently selected from C_{1-6} alkyl, C_{1-6} alkoxy and halo;

X is selected from $(CH_2CH_2O)_n$ and $(CH_2)_n$, and

$n = 1-4$.

2. (Original) The compound according to claim 1, wherein

R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-4} alkyl, C_{1-4} alkoxy, NH_2 , $NH-C_{1-4}$ alkyl, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, NO_2 , CF_3 , OCF_3 and halo;

R^4 is C_{1-6} alkyl,

X is $(\text{CH}_2\text{CH}_2\text{O})_n$, and

n = 1-4.

3. (Currently Amended) The compound according to ~~any of claims 1 and 2~~ claim 1, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, C_{1-4} alkyl, C_{1-4} alkoxy, NH_2 , NH-C_{1-4} alkyl, $\text{N}(\text{C}_{1-4}\text{alkyl})(\text{C}_{1-4}\text{alkyl})$, NO_2 , CF_3 , OCF_3 and halo.
4. (Original) The compound according to claim 3, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, OCH_3 , NH_2 , $\text{N}(\text{CH}_3)_2$ and NO_2 .
5. (Original) The compound according to claim 4, wherein R^1 , R^2 and R^3 are each independently selected from H, OH, and OCH_3 .
6. (Original) The compound according to claim 1, wherein R^4 is unsubstituted Ar.
7. (Original) The compound according to claim 6, wherein R^4 is phenyl.
8. (Original) The compound according to claim 2, wherein R^4 is methyl or ethyl.
9. (Original) The compound according to claim 8, wherein R^4 is methyl.
10. (Original) The compound according to claim 9, wherein n is 2-3.
11. (Original) The compound according to claim 10, wherein n is 3.

12. (Original) A compound selected from:

2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-38)

2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-39)

2-Cyano-5-(3,4-dihydroxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-methoxyethoxy)ethoxy]
ethyl ester (CRIV-42)

2-Cyano-5-(4-hydroxy-3,5-dimethoxyphenyl)-penta-2E,4E-dienoic acid 2-[2-(2-
methoxyethoxy)ethoxy]ethyl ester (CRIV-46); and

2-Cyano-5-(4-hydroxy-3-methoxyphenyl)-penta-2E,4E-dienoic acid benzyl ester (CRIX-79).

13. (Original) A composition comprising a compound according to any one of claims 1 to 12
in admixture with a pharmaceutically acceptable diluent or carrier.

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Original) A method of modulating cell proliferation comprising administering an
effective amount of a compound according to any of claims 1-12, and/or a composition according
to claim 13, to a cell or animal in need thereof.

18. (Original) The method according to claim 17, for inhibiting cell proliferation.

19. (Original) The method according to claim 18 wherein the cell is a malignant hematopoietic cell.

20. (Withdrawn).

21. (Withdrawn).

22. (Withdrawn).

23. (Withdrawn).

24. (Withdrawn).

25. (Withdrawn).

26. (Withdrawn).

27. (Withdrawn).

28. (Withdrawn).

29. (Withdrawn).

30. (Withdrawn).

31. (Withdrawn).

- 32. (Canceled).
- 33. (Canceled).
- 34. (Canceled).
- 35. (Withdrawn).
- 36. (Withdrawn).
- 37. (Withdrawn).
- 38. (New) The compound according to claim 1 in substantially anhydrous form.
- 39. (New) The compound according to claim 1 in crystalline form.